Public, Industry Agree on Biotech

The most important message for biotechnology in the new Office of Technology Assessment's study of public perceptions of the biotechnology industry is that knowledge dispels concern. Based on a nationwide probability sampling conducted last fall by Lou Harris & Associates, the study finds that nearly half of American adults describe themselves as very interested, concerned and/or knowledgeable about science and technology. It also reveals that fully 80 per cent of the American public expects tha

Written byRichard Godown
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

What is the object lesson here? That our chief critic is a dog who has seen his day? That an enlightened electorate has somehow been won over? That despite constant efforts by some to create fear and spread doubt, the potential benefits of biotechnology in health care, agriculture and the environment are widely perceived by a clear-eyed public? Well, not quite.

What does come through is that a properly informed public is most likely to accept some risk. When it is explained that genetically engineered organisms can significantly increase farm production, a majority would be in favor of their use, even when there is a one-in-a-thousand chance of losing some lo cal species of plant or fish. But, the same is not true if the risk is unquantified.

Right now, figures indicate that the vast majority of the public would favor small-scale environmental application of genetically engineered organisms, but less ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies